Answers are grounded in this paper and cite their sources.
In Brief Purpose: To report the safety of intravitreal ocriplasmin injection based on 2 Phase 3 clinical trials in patients with symptomatic vitreomacular adhesion/vitreomacular traction, including when associated with full-thickness macular holes. Methods: Safety analyses were based on 2 completed Phase 3 studies assessing intravitreal ocriplasmin injection. Adverse events (AEs), serious AEs, and suspected adverse drug reactions are reported. The authors also report AEs of special interest from 8 other completed Phase 2 studies and 2 ongoing studies. Results: A total of 465 eyes were injected with ocriplasmin (125 µg), and 187 eyes were treated with placebo injection in Phase 3 studies. Overall AE rate was 69.0% in the placebo group and 76.6% for ocriplasmin-treated patients. Most AEs were in the study eye, mild or moderate in severity, and transient. All suspected adverse drug reactions were ocular; the majority was nonserious, of mild intensity, and transient. Conclusion: Intravitreal ocriplasmin injection provides a generally well-tolerated pharmacologic treatment option for patients with symptomatic vitreomacular adhesion/vitreomacular traction, including when associated with full-thickness macular holes ≤400 µm in diameter. In 2 Phase 3 clinical trials, intravitreal ocriplasmin injection in patients with symptomatic vitreomacular adhesion/vitreomacular traction was generally well tolerated. Most adverse events were ocular, occurred in study eye, and were mild or moderate in severity and transient.
No takes yet. Share an insight, caveat, or question.
Kaiser et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: